HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catterton Tries Its Luck On "Stretch-Mark Cream Turned Anti-Wrinkle Phenom"

This article was originally published in The Rose Sheet

Executive Summary

Private equity firm Catterton Partners augments its cosmeceutical portfolio with the acquisition of an early trailblazer across the cosmetics/pharmaceuticals frontier, StriVectin

You may also be interested in...



StriVectin’s #FightTechNeck Campaign Could Draw Millennials To Anti-Aging

Prestige skin-care brand is positioning a range of StriVectin offerings as preventative against “tech neck,” or signs of aging that result from the repeated strain of checking mobile devices throughout the day. A comprehensive marketing campaign kicks off this fall with the potential to make anti-aging a more relevant category among Millennials.

Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning

FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.

Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning

FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.

Related Content

UsernamePublicRestriction

Register

RS016284

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel